In terms of infrastructure, waterworks, sewage treatment plants, central heating, steam supply, substations, broadband networks and so on. It has been completed, and most of the investment is solved by the self-raised funds of the management Committee. At present, the accumulated tax revenue of the park is 210.50 billion yuan, and the construction loan is10.65438+0 billion yuan. Up to now, biomedicine accounts for 65% of the total amount of the park, and the leading enterprises include 43 GMP factories such as willman Pharmaceutical, Jiuzhitang Qiqi Pharmaceutical, Laimei Kangyuan Pharmaceutical, Veteran Anbang Pharmaceutical, Jintai Pharmaceutical, Taier Pharmaceutical and Erkang Pharmaceutical.
Information technology includes lance technology, the largest investment enterprise in the park, and interface optoelectronics of Taiwan-funded enterprises. Committed to building high-end accessories and complete machines such as mobile phone touch screens, it has become the main supply base for world-renowned brands in this field.
There are 0/8 new drugs under research and 294 patents (trademarks), including 56 invention patents and 0/4 provincial famous trademarks. * * * There are 23 engineering (technical) centers, including provincial 1 1. After years of development, it has formed three characteristic industrial clusters of medicine, information and food, involving environmental protection, new materials and new energy.
In medicine:
(1) Modern Chinese Medicine Innovation and Characteristic Chinese Medicine Industry Cluster. First, the ultra-fine pieces of traditional Chinese medicine produced by Chunguang Jiuhui Modern Chinese Medicine Company in the park won the second prize of national scientific and technological progress in 2009, which is the first in the field of traditional Chinese medicine since Hunan Province was established. Second, the chemical structure modification technology of small molecular active components of traditional Chinese medicine and the separation, extraction and purification of monomer compounds in natural products developed by Leishuo Chemical have formed industrialization. Thirdly, party member Zeng Jianguo, the Democratic Party of Agriculture and Workers, who first proposed that standardized extraction of traditional Chinese medicine was the key link in the modernization of traditional Chinese medicine, established Mecoda Biological Resources Co., Ltd. in the park. The key technology of fresh Chinese medicine extraction developed by him is actively expanding the application of Chinese medicine extracts in human health and animal health drugs. Fourth, the advantages of characteristic Chinese medicine. Songzhi Pill for the treatment of hepatitis C produced by Ji Meng Pharmaceutical Company, An Junning produced by Taier Pharmaceutical Company and Jiedu Capsule produced by Xuanxia Pharmaceutical Company are all national key projects in the Ninth Five-Year Plan and have been put on the market. In addition, the development of traditional Chinese medicine such as Ginkgo biloba and its series products, Pueraria lobata and its series products, which are rich in resources in our province, accounts for more than 30% of the national output value.
(2) High-end API and preparation industry cluster. With Jiudian, Warner University, Dino, willman, Nonferrous Carboplatin, Kangyuan, Dongfeng and other enterprises as the core, the large-scale production of 7-ACA and cephalosporin raw materials and preparations by immobilized invertase technology is under way, with high-end raw materials and corresponding preparation products such as palamivir, pazufloxacin mesylate, colloidal bismuth pectin, pantoprazole sodium, prulifloxacin, levohydroxypropylpiperazine and telmisartan.
(3) Anti-tumor drug industry cluster. First, Zheng Huashenghui oral liquid, a national traditional Chinese medicine protection variety developed by Harbin Cihang Institute of Medicine, was funded by the US government; Second, Changsha Tianci Biomedical Technology Co., Ltd., composed of Liu Jun from Hobson University and Shen Ben from the University of Wisconsin, is the first engineering research center in China based on Industry-University-Research in the field of combinatorial biotechnology. At present, its new anti-tumor and anti-cancer drug "rapamycin" has been mass-produced, and the price of this raw material in the international market has reached $6,543,800 per kilogram. Third, the new anticancer drug "Nuohexin" jointly invested by Dino Pharmaceutical Co., Ltd. and Academy of Military Sciences is about to enter the clinic, and the design and construction of the production workshop has started.
(4) Pharmaceutical excipients industry. Hunan Erkang Pharmaceutical Co., Ltd. is a professional pharmaceutical auxiliary material manufacturer with the most complete varieties, the largest scale and the most complete supporting facilities in China. The company now has 35 domestic exclusive varieties such as silver nitrate, anhydrous sodium carbonate and weak protein silver. In the 20 10 edition of Pharmacopoeia, there are more than 30 quality standards for pharmaceutical excipients, which were revised and formulated by the company with the assistance of several provincial drug inspection institutes and the National Pharmacopoeia Committee. We plan to strengthen assistance in management and technical progress, so that the annual output value will reach more than 3 billion yuan, and our garden will become the main procurement and production center of pharmaceutical excipients in China.
(5) Biological Diagnostic Reagent Industry Group. Academician Zhou led the bio-company's personalized drug diagnosis gene chip, Xinkang's in vitro diagnostic reagents such as syphilis and AIDS, and the bio-company's "colloidal gold immunochromatographic full quantitative analyzer" to develop rapidly in the park. Among them, the team led by Academician Zhou has developed a mature gene detection chip kit for individualized drug therapy of hypertension, which is the first in the world and the technical level is in the leading position in the world. In the next five years, we hope that this industry and its supporting health service industry will form an industrial scale of 565.438+0 billion yuan.
(6) vaccine industry. BCG polysaccharide nucleic acid developed by Xiangya Medical College of Central South University was built in our garden in February 1999, and was acquired by Jiuzhitang, a listed company in 2003. At present, the accumulated tax revenue in the park is more than 300 million yuan. At the same time, the park management committee cooperates with Canadian listed company Microbix to develop an influenza vaccine project with an annual output of 1 100 million people, which will be the third largest vaccine base in the world after completion. In addition, the park has signed a strategic cooperation agreement with Peking University Weiming Group, and Beijing Kexing Biological Products Co., Ltd. is also actively considering building a base in our park.
(7) Functional health care and food industry cluster. At present, six functional health care industrial clusters with health care products as the leading industries, such as Taier Pharmaceutical, Lvzhiyun Bio and Yikang Bio, have been formed, with an annual output value exceeding 10 billion yuan. In addition, in recent years, food enterprises in Wentai area have begun to settle in the park, and the establishment of Master Kong and Yanjin shops has added new vitality to the park.
(8) Animal Health Medicine Industry Group. The main products are agricultural university animal insurance, Shibilong, Guang 'an, Taifeng and other enterprises, mainly new veterinary drugs such as compound Solanum lyratum injection and polypeptide antibiotics. Such product groups strive to occupy 30% of the national market share within three years and become an important industrial cluster in the field of bio-agriculture in the base.